Mirapexin is a dopamine agonist which stimulates dopamine receptors in the brain.
Dopamine is a neurochemical that transmits nerve signals necessary for normal muscle movements.
It is indicated for the treatment of advanced idiopathic Parkinson's disease in combination with levodopa when the effect of levodopa wears off or becomes inconsistent over the course of the disease. According to the World Health Organization, nearly two percent of people in Europe over the age of 65 suffer from Parkinson's disease. Controlled clinical trials involving more than 1,500 patients showed that Mirapexin alleviates motor function difficulties in Parkinson's patients and, in particular, improves the activity in the daily life of these patients. Many patients with Parkinson's disease need multiple medications to treat the different aspects of the disease. Mirapexin shows little interaction with other drugs which makes it an important addition to the choice of treatment.